E-Book Overview
Many researchers believe that GSK-3 and its inhibitors could lead to effective treatments for neurogenerative disorders, type II diabetes, depression and bipolar disorder, and some forms of cancer. This book provides a thorough introduction to GSK-3, presents up-to-date information, and mentions the birth of several chemical families of GSK-3 inhibitors with varying selectivity. It’s a great reference for researchers in drug design and development.
E-Book Content
GLYCOGEN SYNTHASE KINASE 3 (GSK-3) AND ITS INHIBITORS
WILEY SERIES IN DRUG DISCOVERY AND DEVELOPMENT Binghe Wang, Series Editor
Computer Applications in Pharmaceutical Research and Development Edited by Sean Ekins Glycogen Synthase Kinase 3 (GSK-3) and Its Inhibitors: Drug Discovery and Development Edited by Ana Martinez, Ana Castro, and Miguel Medina
GLYCOGEN SYNTHASE KINASE 3 (GSK-3) AND ITS INHIBITORS Drug Discovery and Development
EDITED BY
ANA MARTINEZ ANA CASTRO MIGUEL MEDINA
A JOHN WILEY & SONS, INC., PUBLICATION
Copyright © 2006 by John Wiley & Sons, Inc. All rights reserved. Published by John Wiley & Sons, Inc., Hoboken, New Jersey. Published simultaneously in Canada. No part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, recording, scanning, or otherwise, except as permitted under Section 107 or 108 of the 1976 United States Copyright Act, without either the prior written permission of the Publisher, or authorization through payment of the appropriate per-copy fee to the Copyright Clearance Center, Inc., 222 Rosewood Drive, Danvers, MA 01923, (978) 750-8400, fax (978) 750-4470, or on the web at www.copyright.com. Requests to the Publisher for permission should be addressed to the Permissions Department, John Wiley & Sons, Inc., 111 River S